A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium

PURPOSE. Angiogenesis is an important hallmark of breast cancer growth and progression. Pazopanib, an oral small molecule inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and KIT, has activity across a range of solid tumors. We evaluated the activity...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Taylor, Sara K., Chia, Stephen, Dent, Susan, Clemons, Mark, Agulnik, Mark, Grenci, Pamela, Wang, Lisa, Oza, Amit M., Ivy, Percy, Pritchard, Kathleen I., Leighl, Natasha B.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: AlphaMed Press 2010
Onderwerpen:
Breast Cancer
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228026/
https://ncbi.nlm.nih.gov/pubmed/20682606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0081
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items